Latvia - latvisk - Zāļu valsts aģentūra

auxilia pharma oÜ, estonia - rivaroksabans - apvalkotā tablete - 2,5 mg

Latvia - latvisk - Zāļu valsts aģentūra

auxilia pharma oÜ, estonia - rivaroksabans - apvalkotā tablete - 10 mg

Latvia - latvisk - Zāļu valsts aģentūra

auxilia pharma oÜ, estonia - rivaroksabans - apvalkotā tablete - 15 mg

Latvia - latvisk - Zāļu valsts aģentūra

auxilia pharma oÜ, estonia - rivaroksabans - apvalkotā tablete - 20 mg

Den europeiske union - latvisk - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leikēmija, limfocītu, hroniska, b-šūna - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Latvia - latvisk - Zāļu valsts aģentūra

sandoz d.d., slovenia - rivaroksabans - apvalkotā tablete - 2,5 mg

Latvia - latvisk - Zāļu valsts aģentūra

teva gmbh, germany - rivaroksabans - apvalkotā tablete - 10 mg

Latvia - latvisk - Zāļu valsts aģentūra

teva gmbh, germany - rivaroksabans - apvalkotā tablete - 15 mg

Latvia - latvisk - Zāļu valsts aģentūra

teva gmbh, germany - rivaroksabans - apvalkotā tablete - 20 mg

Den europeiske union - latvisk - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.